Lars Rebien Sørensen says: "I am pleased to welcome Lise Kingo in ExComm. Her promotion is a testimony to the growing strategic importance of our focus on sustainable development and the Triple Bottom Line, and to Lise Kingo's role in driving this focus throughout our organisation."
Commenting on Lars Almblom Jørgensen's and Kåre Schultz's job change Lars Rebien Sørensen says: "Lars Almblom Jørgensen brings many years of international experience and in-depth business understanding to the staff areas. One of his key tasks will be to apply this knowledge and experience to accelerate the internationalisation of Novo Nordisk's People, Quality and Business Development strategies. With his strong implementation skills and energy, Kåre Schultz is the right person to ensure that we maximise the value of the new products we are about to bring to the market and the huge investments we are making these years in new production capacity."
Background information on Stakeholder Relations and Lise Kingo
Stakeholder Relations is a strategic unit in Novo Nordisk. It drives, challenges and monitors the company's commitment to the Triple Bottom Line, keeps the company alert to new trends of sustainable development and helps management understand and manage the new complex business agenda. It is also responsible for interaction with key opinion leaders, reporting and communications on Triple Bottom Line issues.
ExComm's new member, Lise Kingo, holds several academic degrees including an MSc in Responsibility and Business Practice from the University of Bath, United Kingdom. She joined Novo Nordisk's Bioindustrial Group in 1988 as promotion coordinator. During 1992-1999 she held managerial positions within environmental management. In 1999 she was appointed corporate vice president, Stakeholder Relations in Novo Nordisk A/S and later in Novo A/S. She returned to Novo Nordisk A/S in August 2001 as senior vice president, Stakeholder Relations. Lise Kingo is a frequent speaker at international conferences on Corporate Social Responsibility and received Tomorrow Magazine's Environmental Leadership Award in 1998.
Novo Nordisk is a focused healthcare company and the world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. With headquarters in Denmark, Novo Nordisk employs approximately 16,000 people in 68 countries and markets its products in 179 countries. For further company information visit www.novonordisk.com
For further information please contact:
Media:
Outside North America:
Mike Rulis
Phone (direct): (+45) 4442 3573
Outside North America:
Mike Rulis
Phone (direct): (+45) 4442 3573
In North America:
Susan Jackson
Phone (direct): (+1) 609 919 7776
Susan Jackson
Phone (direct): (+1) 609 919 7776
Investors:
Outside North America:
Peter Haahr
Phone (direct): (+45) 4442 1207
Outside North America:
Peter Haahr
Phone (direct): (+45) 4442 1207
Palle Holm Olesen
Phone (direct): (+45) 4442 6175
Phone (direct): (+45) 4442 6175
In North America
Rasmus Jorgensen
Phone (direct): (+1) 212 878 9607
Rasmus Jorgensen
Phone (direct): (+1) 212 878 9607
Stock Exchange Announcement No 8 / 2002